Novo Nordisk A/S

Copenhagen Stock Exchange:NOVO-B.CO

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

Location

Denmark

Market Cap

USD 329.31 B

Share Price

USD 74.11

Avg Daily Volume

5,846,065

Change (1 day)

-1.13%

Change (1 year)

-47.46%

Change (YTD)

-14.64%

Novo Nordisk A/S Dividends Paid for the year ending December 31, 2024: USD -6.11 B

Novo Nordisk A/S Dividends Paid is USD -6.11 B for the year ending December 31, 2024, a 29.92% change year over year. Dividends paid is cash paid to shareholders as a distribution of profits.

Novo Nordisk A/S Dividends Paid for the year ending December 31, 2023 was USD -4.70 B, a 29.50% change year over year.
Novo Nordisk A/S Dividends Paid for the year ending December 31, 2022 was USD -3.63 B, a 10.41% change year over year.
Novo Nordisk A/S Dividends Paid for the year ending December 31, 2021 was USD -3.29 B, a -0.22% change year over year.
Novo Nordisk A/S Dividends Paid for the year ending December 31, 2020 was USD -3.30 B, a 13.43% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Dividends Paid	Common Stock Issued	Common Stock Repurchased	Free Cash Flow

Copenhagen Stock Exchange: NOVO-B.CO

Novo Nordisk A/S

CEO	Mr. Lars Fruergaard Jorgensen
IPO Date	Jan. 6, 2001
Location	Denmark
Headquarters	Novo Alle 1
Employees	77,406
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials

Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.